Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Piper Sandler Downgrades Globus Medical to Neutral

Piper Sandler analyst Matt O'Brien downgrades Globus Medical (NYSE:GMED) from Overweight to Neutral.

byBenzinga Newsdesk

February 9, 2023

1 minute read

Piper Sandler analyst Matt O’Brien downgrades Globus Medical (NYSE:GMED) from Overweight to Neutral.

Vaxart Stock Breaks Out Of Pennant Pattern: Now What?

By Tyler Bundy

Today, 9:59 AM

Vaxart Inc. (NASDAQ: VXRT) shares were trading higher Monday. A company executive will present an overview of the company’s COVID-19 oral vaccine candidate at the World Vaccine & Immunotherapy Congress on Tuesday, Nov. 30.

VXRT

Goldman Sachs Maintains Neutral on Gatos Silver, Lowers Price Target to $4

By Benzinga Newsdesk

Today, 9:59 AM

Goldman Sachs analyst Emily Chieng maintains Gatos Silver (NYSE:GATO) with a Neutral and lowers the price target from $9 to $4.

GATO

Goldman Sachs Initiates Coverage On Thoughtworks Holding with Neutral Rating, Announces Price Target of $30

By Benzinga Newsdesk

Today, 9:59 AM

Goldman Sachs analyst Brian Essex initiates coverage on Thoughtworks Holding (NASDAQ:TWKS) with a Neutral rating and announces Price Target of $30.

TWKS

Cabaletta Bio Q2 EPS $(0.45) Down From $(0.35) YoY

By Benzinga Newsdesk

Today, 9:59 AM

Cabaletta Bio (NASDAQ:CABA) reported quarterly losses of $(0.45) per share. This is a 28.57 percent decrease over losses of $(0.35) per share from the same period last year.

CABA

Piper Sandler Downgrades Globus Medical to Neutral

Related Posts

Vaxart Stock Breaks Out Of Pennant Pattern: Now What?

Goldman Sachs Maintains Neutral on Gatos Silver, Lowers Price Target to $4

Goldman Sachs Initiates Coverage On Thoughtworks Holding with Neutral Rating, Announces Price Target of $30

Cabaletta Bio Q2 EPS $(0.45) Down From $(0.35) YoY